Sugi Predict

Sugi Predict / Compounds / SCHEMBL71597

SCHEMBL71597

SCHEMBL71597

COC1(C)CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ NR1H2 P55055 3/20 0.41
▸ HPGD P15428 1/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ RECQL P46063 1/20 0.37
▸ EPHX1 P07099 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ RORC P51449 2/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ HTT P42858 1/20 0.35
▸ ATM Q13315 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34471645 0.87 USP2 (0.42) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL20228010 0.86 USP2 (0.45) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL28184794 0.83 HPGD (0.43) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL32681668 0.83 HPGD (0.43) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL28438763 0.82 USP2 (0.47) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL17177139 0.82 USP2 (0.50) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL16661978 0.81 USP2 (0.43) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL78026 0.81 USP2 (0.51) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL21937891 0.81 USP2 (0.43) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL21853217 0.81 USP2 (0.43) USP2SMN1; SMN2NR1H2HPGDEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4608835-A1 PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Novo Nordisk A/S (DK) 2025-09-03 — — EP disclosed
CN-120129684-A Purine compound, composition containing same and use thereof 诺和诺德股份有限公司 2025-06-10 — — CN disclosed
WO-2024086939-A1 PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF INVERSAGO PHARMA INC. (CA) 2024-05-02 — — WO disclosed
WO-2024008680-A1 AZETIDINE DERIVATIVES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-01-11 — — WO disclosed
CN-116075505-A Opioid receptor agonist, preparation method and application thereof 天地恒一制药股份有限公司 2023-05-05 — — CN disclosed
WO-2023030319-A1 OPIOID RECEPTOR AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF 天地恒一制药股份有限公司 2023-03-09 — — WO disclosed
US-11396506-B2 Amino acid compounds with unbranched linkers and methods of use PLIANT THERAPEUTICS, INC. (US) 2022-07-26 — — US disclosed
US-20170240519-A1 BENZOFURAN ANALOGUE AS NS4B INHIBITOR CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) 2017-08-24 — — US disclosed
US-20170240519-A1 BENZOFURAN ANALOGUE AS NS4B INHIBITOR CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) 2017-08-24 — — US disclosed
EP-3199530-A1 BENZOFURAN ANALOGUE AS NS4B INHIBITOR Changzhou Yinsheng Pharmaceutical Co., Ltd. (CN) 2017-08-02 — — EP disclosed
EP-1961750-B1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO CO LTD (JP) 2013-09-18 — — EP disclosed
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 — — US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 — — US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 — — US disclosed
US-20110294778-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-01 — — US disclosed
US-20110294778-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-01 — — US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 — — US disclosed
EP-1961750-A1 VLA-4 INHIBITORY DRUG Daiichi Sankyo Company, Limited (JP) 2008-08-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11396506-B2 Amino acid compounds with unbranched linkers and methods of use ITGA2B, ITGB6, ITGB1 USP2 4286/4885SMN1; SMN2 1460/4885NR1H2 4245/4885
US-20110294778-A1 HEPATITIS C INHIBITOR COMPOUNDS ABCC1, CTRC, HAVCR2 USP2 1591/4885SMN1; SMN2 4586/4885NR1H2 1009/4885
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 USP2 4665/4885SMN1; SMN2 4739/4885NR1H2 231/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 USP2 4661/4885SMN1; SMN2 4702/4885NR1H2 234/4885
US-20170240519-A1 BENZOFURAN ANALOGUE AS NS4B INHIBITOR GTF3C4, BRD4, CUL4B USP2 2537/4885SMN1; SMN2 2019/4885NR1H2 1789/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 USP2 4810/4885SMN1; SMN2 4787/4885NR1H2 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.